FOURKITES
Leading real-time supply chain visibility provider FourKites today published its global Premier Carrier List (PCL), which recognises the rapidly growing community of brokers, carriers and 3PLs who are achieving the highest standards of visibility-related operational excellence across all modes of transport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005062/en/
FourKites’ Latest European Premier Carrier List Reflects ROI of High-quality Real-Time Supply Chain Visibility Data (Graphic: Business Wire)
To qualify for the PCL, carriers must demonstrate an ability to provide high-quality, consistent and accurate data on the vast majority of their shipments, thereby enabling their shipper customers and other ecosystem partners to streamline operations, increase the speed of shipping dock turn times, reduce inventory levels and optimise labour costs.
In the first half of 2022, 685 carriers were named to the PCL, which included an 8% increase for carriers based in Europe. These Premier Carriers demonstrated a significantly higher tracking percentage, on average, versus non-PCL carriers. Over the last six months, carriers who qualified for the Premier Carrier List tracked an average of 92.6% of their over-the-road shipments with real-time visibility, while non-PCL carriers tracked only 74.3% of their shipments.
“We partnered with FourKites because we wanted to grow our business,” says Vladas Stončius, CCO, Vlantana. “Increasingly, suppliers expect carriers to provide real-time data on all shipments. Thanks to FourKites, we’re able to do that efficiently and consistently, which has enabled us to win bigger customers and boost our margins.”
Notably, Premier Carriers witnessed higher growth rates than their non-PCL counterparts. In Europe, from H2 2021 to H1 2022, Premier Carriers experienced shipment volume growth of 9%, compared to non-PCL carriers in the region, who saw shipment volume contract 2%.
“Qualifying for FourKites’ Premier Carrier List is an increasingly important distinction for carriers, brokers and 3PLs who need to stand out in an increasingly competitive and volatile market,” said Jason Eversole, Vice President, Carrier Operations & Strategy, FourKites. “We’re pleased to see continued growth in the total number of Premier Carriers, and equally pleased to see the clear business benefits they are experiencing as a result of their visibility-related excellence.”
The Premier Carrier List is available here, where users can access and search the list according to carrier capabilities, transportation modes, geographies serviced and other relevant criteria.
Premier Carriers speak to program benefits:
"Transervice is honored to be recognised as a FourKites Premier Carrier. FourKites has enabled Transervice, and our clients, with unparalleled visibility into our logistics operations. This capability ensures complete transparency throughout the supply chain and promotes efficient resource utilisation. We are proud to partner with FourKites, and we look forward to their continued growth and innovation."
- Tom Poduch, Senior Director, Solutions, at Transervice
“Van den Bosch is always on the lookout for new opportunities to make its supply chain more efficient and sustainable. Fueled by data, insights and knowledge, innovation and digitalisation are key drivers. The qualification for Premier Carrier is a nice recognition and confirmation of our position as the supply changer in bulk.”
- Marrit Hopmans, Data & Applications Manager, Van den Bosch
“As a former employee of FourKites, I’ve experienced firsthand how imperative their technology is to the entire industry. TransLoop is extremely proud to be recognised as a FourKites Premier Carrier. We will continue to do whatever our shipper and carrier partners need us to do for TransLoop to be the most transparent and reliable broker partner in the industry.”
- Nick Reasoner, CEO, TransLoop
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.8 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,100 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit www.fourkites.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
